Pure H2O Bio-Technologies, Inc., Predicts Increases of Failed Water Delivery Systems is Enormous Opportunity for Its Sharehol...

Pure H20 BIO-TECHNOLOGIES, INC. (Pink Sheets: PRHB) announced today that existing hyper-chlorine disinfection and carbon filter-based water treatment systems appear to have limits that suggest a need for improved potable water supplies in hospitals, military installations or remote locations, residences, nursing homes, day-care centers, commercial facilities, recreational facilities, cruise ships and hotels.

Many delivery systems are breaking down due to aging at the point of entry or point of use, which results in high levels of contamination with pathogenic microorganisms. Although the most common contaminants will be organisms such as E. coli, Salmonella, or Pseudomonas, there has been a significant rise in organisms that are resistant to chlorine and related halogens such as fluorine and bromine. The general way metropolitan water districts try to solve the problem is by flushing out the system and introducing high levels of free chlorine (a very toxic substance which is also corrosive to the pipes used to deliver water to the public).

Although halogens can be effective in killing pathogenic bacteria, our intended use of a tetrasilver-tetraoxide disinfectant is far superior for overall removal and/or killing of the newly emerging pathogenic strains.

Pure H2O Bio-Technologies (PRHB) predicts an enormous opportunity for its shareholder base in its plans to capitalize on the need for the world-wide growing demand for improved point-of-entry and point-of-use water treatment delivery systems. This extremely important disinfection technology developed by PRHB will provide an opportunity to address the concerns of clean drinking water not only in the United States but around the world.

Joseph P. Doxey, President of Pure H2O Bio-Technologies, Inc., stated, “The need for a robust potable water disinfection delivery system, that has the overall capacity for treating the emerging threat agents that are not killed by halogen-based/filtration systems, is now completed. We are anxiously awaiting final certification of its delivery system through EPA's contractor, National Sanitation Foundation (NSF).”

The PRHB marketing strategy is based on leveraging the Company’s water purification systems capability to disinfect rather than to simply entrap potential water-borne microbial pathogens in combination with GAC elements. This adds another level of security for prospective customers and end users. There are approximately 30,000 hospitals in the United States. This is the first target market for Pure H20, followed by other areas including, but not limited to, residential, municipal and other countries.

On July 31, 2007, the Company was awarded patent #7250111 regarding one of its delivery systems, and two additional patents are pending which are under review with the U.S. Patent and Trademark Office, Washington, D.C.

Laboratory Test Results:

Disinfection results against representative bacterial and eukaryotic parasitic agents indicate control of enteric coli form and Cryptosporidium microbial organisms. Results: Bactericidal activity ranging from greater than a 6.0 log base10 reduction of the population of Escherichia coli, a gram-negative enteric coli form bacteria (certain strains can cause fatal infections) and Pseudomonas aeruginosa, a gram-negative aerobic bacterium (certain strains can cause fatal organ abscesses). Antimicrobiocidal oocyst activity ranging up to greater than a 1.8 log base10 reduction of a Cryptosporidium oocyst population with Silver TTO™. Cryptosporidium is a pathogenic water-borne microscopic parasite. Silver TTO™ is very effective against pathogenic bacteria including Escherichia coli and Pseudomonas aeruginosa.

For more information and new technical video visit our web-site at www.pureh20biotech.com

The foregoing press release contains forward-looking statements that can be identified by such terminology as "expects," "potential," "suggests," "may," "intends," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations regarding future research, development, and/or commercial results could be affected by, among other things, uncertainties relating to the availability of future financing; unexpected regulatory delays or government regulation generally; the Company's ability to obtain or maintain patent and other proprietary intellectual property protection; and completion in general. Forward-looking statements speak only as to the date they were made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.